围手术期缺血评估-3(POISE-3)的原理与设计:一项评估氨甲环酸和减少低血压策略的随机对照试验
POISE-3是一项大型国际随机对照试验,目标样本量10000例45岁及以上接受非心脏手术且存在心血管或出血并发症风险的患者,采用部分析因设计,评估氨甲环酸1g静脉推注(手术开始和结束时各一次)与安慰剂相比在30天复合出血结局上的优效性及在主要动静脉血栓事件上的非劣效性,同时评估避免低血压策略与避免高血压策略对30天主要心血管事件的影响。
要点
- 氨甲环酸1g静脉推注于手术开始和结束时各一次,与安慰剂比较30天致命性、大出血和关键器官出血复合结局。
- 避免低血压策略与避免高血压策略比较30天主要心血管事件风险,仅纳入服用≥1种慢性降压药的患者。
- 目标样本量10000例,随访至随机化后30天和1年。
核心结论
- POISE-3试验将评估氨甲环酸和避免低血压策略两种干预对非心脏手术患者出血、心血管并发症和死亡率的影响。
研究设计与样本
- 大型国际随机对照试验,采用部分析因设计,目标样本量10000例。
- 纳入≥45岁接受非心脏手术、存在或处于心血管和出血并发症风险的患者。
- 氨甲环酸组于手术开始和结束时各接受1g静脉推注,或匹配安慰剂,患者、医护人员、数据收集者、结局裁定者和研究者均设盲。
- 服用≥1种慢性降压药的患者同时随机分配至避免低血压策略或避免高血压策略,结局裁定者对血压治疗分配设盲。
- 随机化后30天和1年进行随访。
关键数值与推荐
- 氨甲环酸与安慰剂比较的主要复合结局为30天致命性、大出血和关键器官出血,检验优效性。
- 氨甲环酸与安慰剂比较的主要安全性结局为30天主要动脉和静脉血栓事件,检验非劣效性。
- 避免低血压策略与避免高血压策略比较的主要结局为30天主要心血管事件风险。
- 两种血压管理策略的区别在于手术当日晨及术后前2天患者降压药的管理,以及术中目标平均动脉压。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and associated with increased mortality and cardiovascular complications. Tranexamic acid (TXA) is an antifibrinolytic agent with the potential to reduce surgical bleeding; however, there is uncertainty about its efficacy and safety in noncardiac surgery. Although usual perioperative care is commonly consistent with a hypertension-avoidance strategy (i.e., most patients continue their antihypertensive medications throughout the perioperative period and intraoperative mean arterial pressures of 60 mmHg are commonly accepted), a hypotension-avoidance strategy may improve perioperative outcomes. METHODS: The PeriOperative Ischemic Evaluation (POISE)-3 Trial is a large international randomized controlled trial designed to determine if TXA is superior to placebo for the composite outcome of life-threatening, major, and critical organ bleeding, and non-inferior to placebo for the occurrence of major arterial and venous thrombotic events, at 30 days after randomization. Using a partial factorial design, POISE-3 will additionally determine the effect of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of major cardiovascular events, at 30 days after randomization. The target sample size is 10,000 participants. Patients ≥45 years of age undergoing noncardiac surgery, with or at risk of cardiovascular and bleeding complications, are randomized to receive a TXA 1 g intravenous bolus or matching placebo at the start and at the end of surgery. Patients, health care providers, data collectors, outcome adjudicators, and investigators are blinded to the treatment allocation. Patients on ≥ 1 chronic antihypertensive medication are also randomized to either of the two blood pressure management strategies, which differ in the management of patient antihypertensive medications on the morning of surgery and on the first 2 days after surgery, and in the target mean arterial pressure during surgery. Outcome adjudicators are blinded to the blood pressure treatment allocation. Patients are followed up at 30 days and 1 year after randomization. DISCUSSION: Bleeding and hypotension in noncardiac surgery are common and have a substantial impact on patient prognosis. The POISE-3 trial will evaluate two interventions to determine their impact on bleeding, cardiovascular complications, and mortality. TRIAL REGISTRATION: ClinicalTrials.gov NCT03505723. Registered on 23 April 2018.
引用
- Marcucci M, Painter TW, Conen D, et al. Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. Trials. 2022. PMID: 35101083. doi:10.1186/s13063-021-05992-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。